Neuroleptic malignant syndrome is a rare, but potentially life-threatening adverse event associated with the use of neuroleptic agents. We describe the case of a 47-year-old schizophrenic woman who was treated with clozapine for years. The patient developed acute renal failure with pulmonary edema, and underwent mechanical ventilation and hemodialysis.
Acute Kidney Injury ; Antipsychotic Agents ; Clozapine* ; Female ; Humans ; Middle Aged ; Neuroleptic Malignant Syndrome* ; Pulmonary Edema ; Renal Dialysis ; Respiration, Artificial ; Rhabdomyolysis

No abstract available.
Radiography, Thoracic* ; Thorax*

PURPOSE: Endobronchial tuberculosis and bronchogenic cancer are common causes of atelectasis or obstructive pneumonitis in Korea. Differntiation between endobronchial tuberculosis and bronchogenic carcinoma is important for the treatment and prognosis but it is sometimes difficult to differentiate these two lesions with radiologic examinations. The purpose of this study was to find the differential points between endobronchial tuberculosis and bronchogenic carcinoma associated with atelectasis or obstructive pneumonitis. MATERIALS AND METHODS: Forty patients in whom atelectasis or obstructive pneumonitis was detected on chest radiographs comprised the study. A definite mass opacity was not observed on chest radiographs in all patients. In these patients, the causes of obstruction were endobronchial tuberculosis (n=20) and bronchogenic cancer (n=20) which were microbiologically or pathologically confirmed. RESULTS: Double obstructive lesions were more frequently found in endobronchial tuberculosis (8/20) than in bronchogenic cancer (1/20). Multiple calcifications along the bronchial wall and severe distortion of bronchi were observed only in endobronchial tuberculosis (4/20) and associated low density mass at obstruction site was only observed in bronchogenic cancer (6/20). Bronchial dilatation (11/20) and parenchymal calcifications (14/20) distal to obstruction site, air containing bronchogram at post obstructive bronchus (14/20) were more frequently found in endobronchial tuberculosis. Contour bulging at obstruction site (14/20), and only mucus bronchogram at post obstructive bronchus (14/20) were more frequently found in bronchogenic carcinoma. CONCLUSION: In patients with atelectasis or obstructive pneumonitis, endobronchial tuberculosis is characterized by double obstructive lesion, multiple calcifications at the bronchial wall, and severe distortion of the bronchi. Endobronchial carcinoma is characterized by a low density mass at the obstructive site.
Bronchi ; Carcinoma, Bronchogenic* ; Dilatation ; Humans ; Korea ; Mucus ; Pneumonia* ; Prognosis ; Pulmonary Atelectasis* ; Radiography, Thoracic ; Tuberculosis*

The malignant fibrous histiocytoma (MFH) was first introduced in 1963 to refer to a group of soft-issue tumors characterized by a storiform or cartwheel-ike growth pattern and predominantly fibroblastic appearance. It was postulated that they were derived from histiocytes that could assume the appearance and function of fibroblasts. MFH has been recognized to be the most common sarcoma in the soft tissue of late adult life which involves the deep fascia or skeletal muscles of the extremities or retroperitoneum. It has been noted in other organs, however, it rarely arises in the liver. We report two cases of primary malignant fibrous histiocytoma of the liver histopathologically confirmed after surgical resection-storiform pleomorphic and myxoid subtypes in the 55 year old male and 49 year old female patients, respectively, and describes the clinical courses, characteristics and pathologic aspects with review of the related literatures.
Adult ; Extremities ; Fascia ; Female ; Fibroblasts ; Histiocytes ; Histiocytoma, Malignant Fibrous* ; Humans ; Liver* ; Male ; Middle Aged ; Muscle, Skeletal ; Sarcoma

No abstract available.
Adult* ; Femoral Neck Fractures* ; Femur Neck* ; Humans

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis in patients with liver disease, making its accurate assessment essential for managing chronic liver disease. Traditionally, liver biopsy has been the standard method for evaluating hepatic fibrosis. However, due to its invasive nature and the limitation of sampling only a small portion of the liver, it is not suitable for widespread use in chronic liver disease patients. Recently, there has been growing interest in noninvasive tests for assessing hepatic fibrosis, including imaging techniques and serum biomarkers. These noninvasive tests are being continuously developed and are increasingly being utilized to evaluate the prognosis of chronic liver disease patients and to inform clinical practice. This paper reviews the recent trends in noninvasive methods for assessing hepatic fibrosis in patients with chronic liver disease, based on studies published to date.

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis in patients with liver disease, making its accurate assessment essential for managing chronic liver disease. Traditionally, liver biopsy has been the standard method for evaluating hepatic fibrosis. However, due to its invasive nature and the limitation of sampling only a small portion of the liver, it is not suitable for widespread use in chronic liver disease patients. Recently, there has been growing interest in noninvasive tests for assessing hepatic fibrosis, including imaging techniques and serum biomarkers. These noninvasive tests are being continuously developed and are increasingly being utilized to evaluate the prognosis of chronic liver disease patients and to inform clinical practice. This paper reviews the recent trends in noninvasive methods for assessing hepatic fibrosis in patients with chronic liver disease, based on studies published to date.

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis in patients with liver disease, making its accurate assessment essential for managing chronic liver disease. Traditionally, liver biopsy has been the standard method for evaluating hepatic fibrosis. However, due to its invasive nature and the limitation of sampling only a small portion of the liver, it is not suitable for widespread use in chronic liver disease patients. Recently, there has been growing interest in noninvasive tests for assessing hepatic fibrosis, including imaging techniques and serum biomarkers. These noninvasive tests are being continuously developed and are increasingly being utilized to evaluate the prognosis of chronic liver disease patients and to inform clinical practice. This paper reviews the recent trends in noninvasive methods for assessing hepatic fibrosis in patients with chronic liver disease, based on studies published to date.

Hepatic fibrosis is a critical factor in predicting hepatocellular carcinoma occurrence and prognosis in patients with liver disease, making its accurate assessment essential for managing chronic liver disease. Traditionally, liver biopsy has been the standard method for evaluating hepatic fibrosis. However, due to its invasive nature and the limitation of sampling only a small portion of the liver, it is not suitable for widespread use in chronic liver disease patients. Recently, there has been growing interest in noninvasive tests for assessing hepatic fibrosis, including imaging techniques and serum biomarkers. These noninvasive tests are being continuously developed and are increasingly being utilized to evaluate the prognosis of chronic liver disease patients and to inform clinical practice. This paper reviews the recent trends in noninvasive methods for assessing hepatic fibrosis in patients with chronic liver disease, based on studies published to date.